ASKA Pharmaceutical Co., Ltd. reported consolidated earnings results for the first quarter ended June 2019. For the quarter, the company reported net sales of JPY 13,991 million against JPY 12,761 million a year ago. Operating income was JPY 837 million against JPY 1,217 million a year ago. Profit attributable to owners of parent was JPY 563 million against JPY 1,062 million a year ago.

The company provided consolidated earnings guidance for the year ending March 2020. For the year, the company expects net sales of JPY 53,000 million, operating income of JPY 2,000 million, and profit attributable to owners of parent of JPY 1,000 million.